58 related articles for article (PubMed ID: 23159618)
1. Establishment of a human cell line stably overexpressing mouse Nip45 and characterization of Nip45 subcellular localization.
Hashiguchi K; Ozaki M; Kuraoka I; Saitoh H
Biochem Biophys Res Commun; 2013 Jan; 430(1):72-7. PubMed ID: 23159618
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for regulation of poly-SUMO chain by a SUMO-like domain of Nip45.
Sekiyama N; Arita K; Ikeda Y; Hashiguchi K; Ariyoshi M; Tochio H; Saitoh H; Shirakawa M
Proteins; 2010 May; 78(6):1491-502. PubMed ID: 20077568
[TBL] [Abstract][Full Text] [Related]
3. Puromycin induces SUMO and ubiquitin redistribution upon proteasome inhibition.
Matsumoto H; Saitoh H
Biochem Biophys Res Commun; 2016 Jul; 476(3):153-8. PubMed ID: 27181354
[TBL] [Abstract][Full Text] [Related]
4. SUMO-2/3 conjugates accumulating under heat shock or MG132 treatment result largely from new protein synthesis.
Castorálová M; Březinová D; Svéda M; Lipov J; Ruml T; Knejzlík Z
Biochim Biophys Acta; 2012 Apr; 1823(4):911-9. PubMed ID: 22306003
[TBL] [Abstract][Full Text] [Related]
5. PIAS1-mediated sumoylation promotes STUbL-dependent proteasomal degradation of the human telomeric protein TRF2.
Her J; Jeong YY; Chung IK
FEBS Lett; 2015 Oct; 589(21):3277-86. PubMed ID: 26450775
[TBL] [Abstract][Full Text] [Related]
6. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors.
Lin DY; Huang YS; Jeng JC; Kuo HY; Chang CC; Chao TT; Ho CC; Chen YC; Lin TP; Fang HI; Hung CC; Suen CS; Hwang MJ; Chang KS; Maul GG; Shih HM
Mol Cell; 2006 Nov; 24(3):341-54. PubMed ID: 17081986
[TBL] [Abstract][Full Text] [Related]
7. Proteins with two SUMO-like domains in chromatin-associated complexes: the RENi (Rad60-Esc2-NIP45) family.
Novatchkova M; Bachmair A; Eisenhaber B; Eisenhaber F
BMC Bioinformatics; 2005 Feb; 6():22. PubMed ID: 15698469
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
Bailey D; O'Hare P
Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability.
Latonen L; Moore HM; Bai B; Jäämaa S; Laiho M
Oncogene; 2011 Feb; 30(7):790-805. PubMed ID: 20956947
[TBL] [Abstract][Full Text] [Related]
10. Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor.
Tirard M; Almeida OF; Hutzler P; Melchior F; Michaelidis TM
Mol Cell Endocrinol; 2007 Mar; 268(1-2):20-9. PubMed ID: 17314004
[TBL] [Abstract][Full Text] [Related]
11. Comparative proteomic analysis identifies a role for SUMO in protein quality control.
Tatham MH; Matic I; Mann M; Hay RT
Sci Signal; 2011 Jun; 4(178):rs4. PubMed ID: 21693764
[TBL] [Abstract][Full Text] [Related]
12. TRAF1 regulates Th2 differentiation, allergic inflammation and nuclear localization of the Th2 transcription factor, NIP45.
Bryce PJ; Oyoshi MK; Kawamoto S; Oettgen HC; Tsitsikov EN
Int Immunol; 2006 Jan; 18(1):101-11. PubMed ID: 16352630
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML.
Weisshaar SR; Keusekotten K; Krause A; Horst C; Springer HM; Göttsche K; Dohmen RJ; Praefcke GJ
FEBS Lett; 2008 Sep; 582(21-22):3174-8. PubMed ID: 18708055
[TBL] [Abstract][Full Text] [Related]
14. The Bcl-2/Bcl-xL inhibitor BH3I-2' affects the dynamics and subcellular localization of sumoylated proteins.
Plourde MB; Morchid A; Iranezereza L; Berthoux L
Int J Biochem Cell Biol; 2013 Apr; 45(4):826-35. PubMed ID: 23375957
[TBL] [Abstract][Full Text] [Related]
15. Daxx mediates SUMO-dependent transcriptional control and subnuclear compartmentalization.
Shih HM; Chang CC; Kuo HY; Lin DY
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1397-400. PubMed ID: 18031230
[TBL] [Abstract][Full Text] [Related]
16. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
[TBL] [Abstract][Full Text] [Related]
17. SUMO regulates the cytoplasmonuclear transport of its target protein Daxx.
Chen A; Wang PY; Yang YC; Huang YH; Yeh JJ; Chou YH; Cheng JT; Hong YR; Li SS
J Cell Biochem; 2006 Jul; 98(4):895-911. PubMed ID: 16475184
[TBL] [Abstract][Full Text] [Related]
18. Protein inhibitor of activated STAT Y (PIASy) and a splice variant lacking exon 6 enhance sumoylation but are not essential for embryogenesis and adult life.
Wong KA; Kim R; Christofk H; Gao J; Lawson G; Wu H
Mol Cell Biol; 2004 Jun; 24(12):5577-86. PubMed ID: 15169916
[TBL] [Abstract][Full Text] [Related]
19. An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16.
Bund T; Spoden GA; Koynov K; Hellmann N; Boukhallouk F; Arnold P; Hinderberger D; Florin L
Cell Microbiol; 2014 Aug; 16(8):1179-200. PubMed ID: 24444361
[TBL] [Abstract][Full Text] [Related]
20. The ubiquitin-like modifier FAT10 interacts with HDAC6 and localizes to aggresomes under proteasome inhibition.
Kalveram B; Schmidtke G; Groettrup M
J Cell Sci; 2008 Dec; 121(Pt 24):4079-88. PubMed ID: 19033385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
